RESEARCH ARTICLE

The Expression of Programmed Death-1 on CD4$^+$ and CD8$^+$ T Lymphocytes in Patients with Type 2 Diabetes and Severe Sepsis

Yumei Jia$^{1*}$, Yongzhen Zhao$^{2*}$, Chunsheng Li$^2$, Rui Shao$^2$

$^1$ Department of Endocrinology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, $^2$ Department of Emergency Medicine, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China

These authors contributed equally to this work.

* loscyyy@163.com

Abstract

Objective

To investigate the expression of Programmed death-1 (PD-1) on T lymphocytes in patients with type 2 diabetes mellitus (T2DM) and severe sepsis, we determined PD-1 expression on CD4$^+$ and CD8$^+$ T lymphocytes of patients with T2DM, severe sepsis, and T2DM combined with severe sepsis.

Research Design and Methods

This prospective and observational study included 50 healthy controls, 80 cases of T2DM without infection (T2DM group), 88 cases of severe sepsis without T2DM (SS group), and 77 cases of severe sepsis combined with T2DM (SS+T2DM group). Expression of peripheral blood PD-1$^+$ CD4$^+$ T cells and PD-1$^+$ CD8$^+$ T cells were compared between these 4 groups. Then, 28-day survival of the SS and SS+T2DM patients was assessed, and the expression of PD-1 on T cells was also compared between survivors and non-survivors.

Results

Percentages of PD-1$^+$ CD4$^+$ T cells and PD-1$^+$ CD8$^+$ T cells were higher in the T2DM group than in the healthy control group, and were highest in the SS and SS+T2DM groups. However, the expression of PD-1 on T cells and the mortality showed no significant difference between the SS and SS+T2DM groups. The expression of PD-1 on T cells was higher in non-survivors than survivors, but within the survivor group or non-survivor group, no difference can be detected between those with T2DM and those without T2DM.

Conclusion

The expression of PD-1 on T cells was increased in both T2DM and severe septic patients, but combining T2DM did not cause a further increase on the PD-1 expression in patients with severe sepsis.
Introduction

Sepsis is a common critical illness in clinical practice, and immunosuppression is an important cause of deterioration of severe sepsis [1]. With the increase in the incidence of type 2 diabetes mellitus (T2DM), its effect on sepsis and the underlying mechanism are attracting more and more attention [2]. T2DM is conventionally considered mostly a metabolic disorder. Insulin resistance and insufficient insulin secretion are considered the core of this disease, which, however, doesn’t well explain the common clinical and biochemical characteristics seen in T2DM patients. In recent years, more and more studies indicate that the pathogenesis of T2DM involves immune dysfunction, and T2DM can be considered somewhat a chronic inflammatory disease [3,4]. Impaired immunity in patients with diabetes may increase the risk of infection, however, the exact effect of diabetes on patients with severe sepsis remains to be studied.

Programmed death-1 (PD-1) is a novel member of the CD28 superfamily. It’s a negative co-stimulatory factor that mediates negative co-stimulatory signal [5]. PD-1 can effectively inhibit functioning and proliferation of the T cells, and reduce IL-2, IL-10 and IFN-γ secretion [6,7], playing an important role in immune regulation [8]. Studies have shown that, PD-1 expression is increased in septic patients, and is closely related to hospital infection and mortality [9,10]. Such effect may be attributed to the immunosuppression effect of PD-1 [11]. Studies about the role of PD-1 on diabetes mostly refer to type 1 diabetes mellitus (T1DM) [12–14], but the role of PD-1 on T2DM has rarely been reported. Furthermore, no study has reported the expression of PD-1 on T cells in type 2 diabetic patients with severe sepsis. This study assessed the expression of PD-1 on the surface of peripheral blood T lymphocytes in healthy volunteers, T2DM patients, severe septic patients, and patients with both T2DM and severe sepsis, to investigate the expression PD-1 on T lymphocytes in patients with T2DM and severe sepsis, and determine the effect of T2DM on the expression of PD-1 in the immune system of patients with severe sepsis.

Materials and Methods

Subjects

This observational clinical study was conducted in Beijing Chao-Yang Hospital, a tertiary care teaching hospital, between August 2014 and July 2015. Severe sepsis combined with T2DM (the SS+T2DM group) and severe sepsis without T2DM (the SS group) were enrolled from the emergency department. Meanwhile, infection-free T2DM patients (the T2DM group) who shared a similar history of diabetes and were taking similar drugs as the SS +T2DM group, were selected from the department of endocrinology. In addition, healthy volunteers were recruited as control. Age and gender were matched among the 4 groups. It was required that patients of the T2DM group and the healthy control group should have shown no systemic or local inflammation and had no anti-inflammation drugs in the past week before examination. The diagnosis of diabetes was based on previous hospital records as well as the examination of this time, and the diagnosis of T2DM was consistent with the criteria for diagnosis and classification of diabetes mellitus issued by the American Diabetes Association in 2013 [15]. The diagnosis of severe sepsis was in line with the diagnostic criteria listed in the 2012 International Guidelines for Management of Severe Sepsis and Septic Shock [16]. The exclusion criteria were: age < 18 years, surgical trauma, hematological disease, autoimmune disease, HIV/AIDS, disease of the liver (such as hepatitis, cirrhosis), end-stage renal disease (requiring dialysis), tumors, pregnancy, receiving hormone treatment. Eligible patients may have previously one or more of the following complications: chronic obstructive
pulmonary disease (COPD), cardiovascular disease (coronary heart disease and/or heart failure), chronic kidney disease (not including patients that require dialysis) and cerebrovascular disease. Comparison was first performed among the healthy control group, the T2DM group, the SS group, and the SS+T2DM group. Then all patients with severe sepsis (with or without T2DM) were followed up for 28 days, and 28-day mortality of these patients was recorded. The patients who were discharged earlier than 28 days were assessed by telephone to define outcomes. And PD-1 expression was compared between survivors and non-survivors. This study was in line with medical ethics standards, and was approved by the Ethics Committee of Beijing Chaoyang Hospital, and was performed with informed consent from the patients or their families.

**Data Collection**

Age, gender, address, telephone number, vital signs, past medical history, treatment for diabetes prior to admission, blood routine examination, blood gas analysis, liver and renal function, hemoglobin A1c (HbA1c), blood glucose levels on admission, high sensitivity C-reactive protein (Hs-CRP), chest X-ray, and results of sputum, blood or urine culture were recorded for all subjects included. HbA1c was measured by Tosoh HLC-723 G8 automatic glycohemoglobin analyzer (Tosoh Corporation, Tokyo, Japan) with the principle of high-performance liquid chromatography. Blood glucose was detected on Siemens ADVIA 2400 automatic biochemistry analyzer (Siemens Diagnostics, Tarrytown, NY, USA) by using glucose oxidase method. Hs-CRP was analyzed by immunoturbidimetric assay (Orion Diagnostica Oy, Espoo, Finland) on the Beckman DXC800 analyzer (Beckman Coulter Inc., Brea, CA, USA). 4ml ulnar vein blood of each subject was taken upon admission and stored in ethylenediamine tetraacetic acid (EDTA) anticoagulant tubes for flow cytometry analysis. The Acute Physiology and Chronic Health Evaluation System II (APACHE II) score and the Sequential Organ Failure Assessment (SOFA) score were determined within 24 hours.

**Flow Cytometry**

The cells were stained and erythrocytes were lysed by researchers who were blinded to the clinical data. According to the manufacturer’s recommendations, monoclonal antibodies and their isotype controls were used: BV421-labeled anti-PD-1 (5 μl, clone EH12.1; BD Bioscience, San Jose, CA, USA), APC-H7 labeled anti-CD3 (5 μl, clone SK7; BD Bioscience), FITC-labeled anti-CD4 (5 μl, clone OKT4; eBioscience, San Diego, CA, USA), FITC-labeled anti-CD8 (20 μl, clone RPA-T8; BD Bioscience) per 100 μl of whole blood. Samples were measured on the Gallios™ Flow Cytometer (Beckman Coulter, Inc.) and analyzed by Gallios Software Version 1.0 (Beckman Coulter, Inc.). Lymphocytes were gated by forward scatter and side scatter, and T cells subsets were further distinguished by CD3⁺ and CD4⁺ staining, or CD3⁺ and CD8⁺ staining. At least 3,000 CD4⁺ T cells or CD8⁺ T cells were analyzed from each sample. Results are expressed as percentage of PD-1⁺CD4⁺ and PD-1⁺CD8⁺ T cells (Fig 1).

**Statistical Analysis**

All data were analyzed using the SPSS17.0 software (SPSS Inc., Chicago, IL, USA). Age, scores, and each examination results were presented as medians with interquartile ranges [M(Q₁, Q₃)], and the Mann-Whitney U test was applied; Categorical clinical variables were assessed by chi-square test; correlation between the factors were analyzed by Spearman correlation test; P<0.05 was considered statistically significant.
Results

Characteristics of the Patients

A total of 245 patients who met the eligibility criteria and 50 healthy controls were enrolled in this study. There were 80 cases in the T2DM group, 88 cases in the SS group, and 77 cases in the SS+T2DM group. 29 patients failed to survive in the SS group, and 24 patients failed to survive in the SS+T2DM group. Patients of the T2DM group showed a higher level of Hs-CRP, HbA1c, blood glucose levels on admission, and lower lymphocyte count than the healthy controls. The SS and SS+T2DM group showed higher white blood cell count, and Hs-CRP than the healthy control and T2DM group, and lymphocyte count further decreased. The SS +T2DM group had higher HbA1c and blood glucose levels on admission than the T2DM group, but no significant difference was detected in white blood cell count, lymphocyte count,
Hs-CRP, APACH II score, SOFA score, and 28-day mortality between the SS and SS+T2DM groups. The SS and SS+T2DM groups showed higher rate of COPD complication than the T2DM group, but rates of other complications showed no significant difference among the 3 groups (Table 1).

The Expression of PD-1+ CD4+ T Cells and PD-1+ CD8+ T Cells

Percentages of PD-1+ CD4+ T cells and PD-1+ CD8+ T cells were significantly increased in the T2DM, SS, and SS+T2DM groups than in the healthy control group, and were the highest in the SS+T2DM and SS groups, but no significant difference was detected between the SS +T2DM group and SS group (Fig 1, Table 1). Similar results were shown when flow cytometry data were expressed as mean fluorescence intensity (MFI) (Table 1).

The Correlation between the Expression of PD-1 on T Cells and the Severity of Illness

For patient of the T2DM group, percentages of PD-1+ CD4+ T cells and PD-1+ CD8+ T cells were both positively correlated with Hs-CRP levels (r = 0.452 and 0.376 respectively, P<0.001).

### Table 1. Characteristics of the four groups of patients.

| Characteristics                  | Healthy control (n = 50) | T2DM (n = 80) | Severe sepsis without T2DM (n = 88) | Severe sepsis with T2DM (n = 77) |
|---------------------------------|--------------------------|---------------|-----------------------------------|---------------------------------|
| Male, n (%)                     | 27(54.0)                 | 43(53.8)      | 46(52.3)                          | 41(53.2)                        |
| Age, years                      | 61(52–71)                | 61(50–72)     | 62(53–71)                         | 64(53–71)                       |
| WBC (x10^9/L)                   | 6.67(5.89–7.73)          | 6.81(6.06–8.10) | 14.10(11.80–17.35) **             | 13.50(10.52–16.78) **           |
| Lymphocytes (x10^9/L)           | 2.68(2.32–3.05)          | 2.37(1.92–2.93) * | 0.87(0.64–1.41) **               | 0.90(0.50–1.55) **             |
| Hs-CRP (mg/L)                   | 0.50(0.24–1.02)          | 1.94(1.30–3.93) * | 12.96(10.65–14.39) **            | 13.08(11.13–14.58) **           |
| HbA1c (%)                       | 5.70(5.23–6.05)          | 9.55(8.80–11.10) e △ | 5.73(5.22–6.10)                 | 11.30(8.65–13.30) △            |
| Glucose levels (mmol/L)         | 5.23(4.81–5.64)          | 8.33(6.68–10.28) * | 7.11(6.10–9.23)                  | 11.80(7.30–16.25) △            |
| APACHE II score                 | /                        | /             | 19(15–25)                         | 20(16–23)                       |
| SOFA score                      | /                        | /             | 11(8–14)                         | 11(8–15)                       |
| Percentage of PD-1+CD4+ T cells (%) | 25.98(22.38–29.15)       | 32.78(27.01–38.16) * | 39.60(31.42–48.02) #             | 40.34(30.79–46.13) #           |
| Percentage of PD-1+CD8+ T cells (%) | 21.48(16.70–25.39)       | 32.90(23.89–40.51) * | 38.72(29.84–51.59) #             | 41.02(31.55–48.55) #           |
| MFI of PD-1+CD4+ T cells        | 1.32(1.21–1.85)          | 4.54(3.70–4.83) * | 5.78(3.68–8.12)                  | 5.67(4.51–7.30) #              |
| MFI of PD-1+CD8+ T cells        | 1.36(0.97–2.55)          | 4.94(4.15–5.57) * | 5.69(4.29–8.13) **               | 5.77(4.40–7.52) **             |
| Comorbidities, n (%)            | /                        | /             | /                                 | /                               |
| COPD                            | /                        | 16(20.0)      | 36(40.9) #                        | 29(37.7) #                      |
| Cardiovascular disease          | /                        | 30(37.5)      | 34(38.6)                          | 31(40.3)                        |
| Chronic renal disease           | /                        | 19(23.8)      | 18(20.5)                          | 21(27.3)                        |
| Cerebrovascular disease         | /                        | 6(7.5)        | 13(14.8)                          | 12(15.6)                        |
| Mortality, n (%)                | /                        | /             | 29(33.0)                          | 24(31.2)                        |

T2DM, Type 2 diabetes mellitus; WBC, white blood cells; Hs-CRP, high sensitivity C-reactive protein; HbA1c, hemoglobin A1c; APACHE II, acute physiology and chronic health evaluation system II; SOFA, sequential organ failure assessment; COPD, chronic obstructive pulmonary disease; PD-1, programmed death-1; MFI, mean of fluorescence intensity.

* compared to the Health control group P<0.05;
# compared to the T2DM group P<0.05;
△ compared to the Severe sepsis without T2DM group P<0.05.

doi:10.1371/journal.pone.0159383.t001
for both) (Fig 2a and 2b), but showed no significant correlation with HbA1c, blood glucose levels on admission (P > 0.05). For patients with severe sepsis (with and without T2DM), the percentages of PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells were positively correlated with APACHE II score (r = 0.627 and 0.649 respectively, P < 0.001) or with SOFA score (r = 0.566 and 0.556 respectively, P < 0.001) (Fig 2c–2f), but showed no significant correlation with Hs-CRP, HbA1c, blood glucose levels on admission or lymphocyte count (P > 0.05). Positive correlations were also observed when MFI of PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells were correlated with APACHE II score (r = 0.345 and 0.245 respectively, P < 0.001) or with SOFA score (r = 0.376 and 0.320 respectively, P < 0.001).

Comparison between the Survivor Group and Non-Survivor Group
Percentages of PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells, MFI of PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells, APACHE II score and SOFA score were significantly higher in non-survivors than survivors among severe septic patients with or without T2DM (P < 0.05), the non-survivors of the SS+T2DM group were older than survivors (P < 0.05), but within the survivor group or non-survivor group, no difference could be detected between those with T2DM and those without T2DM (P > 0.05) (Table 2, Fig 3). Gender, white blood cell count, lymphocyte count, Hs-CRP, HbA1c, blood glucose levels on admission, as well as the site of infection all showed no significant difference between the survivor group and non-survivor group (P > 0.05).

Discussion
PD-1 is a negative co-stimulatory molecule that negatively regulates the immune system. PD-1 transduces an inhibitory signal that leads to inhibition of activation, proliferation, and functioning of the effector cells [7]. In this study, it was found that PD-1 levels on peripheral blood T lymphocytes was increased in both the T2DM patients and those with severe sepsis compared to healthy controls, and those with severe sepsis showed higher PD-1 levels than T2DM, suggesting that both T2DM patients and those with severe sepsis had immune suppression. However, no additive effect was observed when T2DM and severe sepsis were combined, patients with severe sepsis combining T2DM had similar expression of PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells, and similar mortality rate as those with severe sepsis only. Our results suggest that T2DM did not increase 28-day mortality in patients with severe sepsis, nor did it increase the expression of PD-1 on T cells.

More and more studies suggest that T2DM is an immune-related chronic inflammatory disease, and when it affects the islet, decreased number of β cells and insulin secretion disorder may occur [17]. T2DM patients and animal model of T2DM both showed immune cell invasion of the islet [18]. It was found in this study that expressions of peripheral blood PD-1⁺ CD4⁺ T cells and PD-1⁺ CD8⁺ T cells were increased in the T2DM patients compared with healthy control, and were positively correlated with Hs-CRP level. Hs-CRP as a marker of inflammation has been widely used in clinical research. It has been reported that increased Hs-CRP is of significant diagnostic value for the severity of diabetes, diabetic nephropathy, and diabetic coronary heart disease [19–21]. So, the expression of PD-1 on T cells could be correlated with the severity of diabetes. It has also been reported that PD-1 levels are increased on CD4⁺ CD28⁻ T cells of T2DM patients, which are closely correlated with the severity of diabetic atherosclerotic macrovascular diseases [22].

The one of the major causes of death in patients with severe sepsis is immune suppression caused by damages to the immune system [1, 23], in which the negative co-stimulatory molecules such as PD-1 may play a major role [11]. Autopsy results demonstrated that PD-1 levels...
Fig 2. Correlation of the percentage of PD-1+ T cells with Hs-CRP and the score system. (a) Correlation of Hs-CRP and the percentage of PD-1+CD4+ T cells in the patients with T2DM. (b) Correlation of Hs-CRP and the percentage of PD-1+CD8+ T cells in the patients with T2DM. (c) Correlation of the APACHE II score and the percentage of PD-1+CD4+ T cells in the patients with severe sepsis (with and without T2DM). (d) Correlation of the APACHE II score and the percentage of PD-1+CD8+ T cells in the patients with severe sepsis (with and without T2DM). (e) Correlation of the SOFA score and the percentage of PD-1+CD4+ T cells in the patients with severe sepsis (with and without T2DM). (f) Correlation...
were significantly increased on the surface of lymphocytes in the spleen of the deceased [1]. Animal experiments also demonstrated higher PD-1 expression on the surface of peripheral blood macrophages and monocytes in the mouse model of sepsis [24], and administration of PD-1 antagonist significantly improved survival of these mice [25]. Recent clinical trials also indicate that PD-1 expression on peripheral blood T cells is significantly increased in patients with sepsis [9, 10, 26]. Such increase in PD-1 expression on T cells was also obvious in patients with severe sepsis as included in this study, and PD-1 levels were positively correlated with APACHE II and SOFA scores, suggesting that PD-1 levels were closely related with severity of the disease. This study found that PD-1 levels on T cells were higher in the non-survivors, who might be associated with more severe immunosuppression. The expression of PD-1 on T cells showed no significant difference between the SS group and the SS+T2DM group, possibly because T2DM-related PD-1 increase was not so obvious as that caused by severe sepsis, it’s only slightly increased compared with healthy controls. Animal experiment demonstrated that PD-1 has a protective effect on T1DM. Injecting PD-1 antibody into nonobese diabetic (NOD) mice model of diabetes accelerated occurrence of diabetes, and it also plays a role in islet inflammation and production of T-cell pro-inflammatory cytokines [12]. Lack of the PD-1

Table 2. Comparison between the survivors and the non-survivors.

| Characteristics                        | Severe sepsis without T2DM | Severe sepsis with T2DM |
|----------------------------------------|----------------------------|-------------------------|
|                                        | Survivors (n = 59)        | Non-survivors (n = 29)  | p^a                      | Survivors (n = 53)        | Non-survivors (n = 24)  | p^b                      |
| Male, n (%)                            | 32(54.2)                  | 14(48.3)                | 0.601                    | 30(56.6)                  | 11(45.8)                | 0.383                    |
| Age, years                             | 61(50–70)                 | 66(59–71)               | 0.053                    | 63(45–70)                 | 67(59–74)               | 0.028                    |
| WBC (×10^9/L)                          | 14.90(12.70–17.20)        | 11.80(10.30–17.55)      | 0.063                    | 13.37(10.21–16.78)        | 14.38(11.57–17.50)      | 0.538                    |
| Lymphocytes (×10^9/L)                  | 0.86(0.65–1.35)           | 0.87(0.55–1.63)         | 0.793                    | 0.90(0.45–1.45)           | 1.05(0.55–1.58)         | 0.640                    |
| Hs-CRP (mg/L)                          | 12.88(10.68–14.21)        | 13.15(9.90–14.96)       | 0.570                    | 13.08(10.68–14.47)        | 13.05(11.33–14.88)      | 0.779                    |
| HbA1c (%)                              | 5.72(5.00–6.11)           | 5.74(5.39–6.06)         | 0.716                    | 11.20(8.70–13.20)         | 11.65(8.63–13.50)       | 0.700                    |
| Glucose levels (mmol/L)                | 7.00(6.11–9.16)           | 7.25(6.00–9.83)         | 0.526                    | 12.20(7.60–16.85)         | 11.40(5.28–16.13)       | 0.269                    |
| APACHE II score                        | 17(13–22)                 | 25(21–28)               | <0.001                   | 18(14–21)                 | 25(20–27)               | <0.001                   |
| SOFA score                             | 10(7–13)                  | 14(9–16)                | 0.001                    | 10(7–13)                  | 14(12–18)               | 0.001                    |
| Percentage of PD-1^+CD4^+ T cells (%)   | 35.10(28.62–42.93)        | 47.76(40.19–51.73)      | <0.001                   | 38.12(28.85–43.12)        | 44.50(40.16–56.90)      | <0.001                   |
| Percentage of PD-1^+CD8^+ T cells (%)   | 32.99(27.90–43.80)        | 50.80(38.75–61.10)      | <0.001                   | 36.34(27.77–45.68)        | 48.28(40.72–62.87)      | <0.001                   |
| MFI of PD-1^+CD4^+ T cells             | 4.98(3.26–7.01)           | 7.29(5.61–9.14)         | 0.002                    | 5.43(4.29–6.33)           | 6.92(5.46–7.80)         | 0.011                    |
| MFI of PD-1^+CD8^+ T cells             | 5.24(4.05–7.71)           | 7.45(4.99–9.43)         | 0.030                    | 5.50(4.18–6.32)           | 7.12(5.35–8.37)         | 0.015                    |
| Primary site of infection, n (%)       | 32(54.2)                  | 21(72.4)                | 0.102                    | 28(54.2)                  | 17(70.8)                | 0.138                    |
| Respiratory                            | 12(20.3)                  | 6(20.7)                 | 0.969                    | 12(22.6)                  | 4(16.6)                 | 0.768                    |
| Abdominal                              | 8(13.6)                   | 2(6.9)                  | 0.570                    | 7(13.2)                   | 1(4.2)                  | 0.423                    |
| Urinary                                | 3(5.1)                    | 0                      | /                       | 3(5.7)                    | 0                      | /                       |
| Cerebral                               | 4(6.8)                    | 0                      | /                       | 3(5.7)                    | 2(8.3)                  | 1.000                    |

T2DM, Type 2 diabetes mellitus; WBC, white blood cells; Hs-CRP, high sensitivity C-reactive protein; HbA1c, hemoglobin A1c; APACHE II, acute physiology and chronic health evaluation system II; SOFA, sequential organ failure assessment; PD-1, programmed death-1; MFI, mean of fluorescence intensity.

^a The survivors compared with the non-survivors in the patients of Severe sepsis without T2DM.

^b The survivors compared with the non-survivors in the patients of Severe sepsis with T2DM.

doi:10.1371/journal.pone.0159383.g002
inhibitory signal could lead to infiltration of CD8+ T cells into islet, where they destroy islet β cells and release inflammatory cytokines [27]. Similarly, reports on PD-1 and T2DM also indicate that the increase of PD-1 levels in the mice model of T2DM nephropathy was a compensatory response to reduce inflammation [28]. So, it is suspected that PD-1 levels increase in DM may represent some compensatory self-protection mechanism, while the marked increase of PD-1 levels in severe sepsis may represent excessive activation of this negative regulation mechanism, which results in adverse consequences. Because the effect of PD-1 on T cells in T2DM and severe sepsis is different, the increase of PD-1 on T cells in T2DM and severe sepsis can not be simply added to each other, and combining T2DM do not cause a further increase on the expression of PD-1 in patients with severe sepsis.

It has been reported that diabetes may increase the risk of infection and sepsis [29, 30]. In this study, blood glucose levels on admission and HbA1c of the SS+T2DM group were higher than that of the T2DM group, suggesting that poor glycemic control may be one of the causes for severe infection among patients with T2DM. Although diabetes seems to be a risk factor for infection, its effect on the prognosis of patients with sepsis remains controversial [31]. In a retrospective cohort study on patients with severe sepsis admitted to ICU, it was found that those with T2DM showed no significant differences with those without, as to number of organ dysfunctions, length of hospital stay, and 90-day hospital mortality [32]. In this study, APACHE II score and SOFA score also showed no significant difference between the SS group and SS +T2DM group, which meant that T2DM did not aggravate the conditions of patients with severe sepsis. Many researches indicated that the incidence of sepsis and the risk of mortality were increased in the elderly patients [33, 34], our study also found the non-survivors of the SS +T2DM group were older than survivors. But within the survivor group or non-survivor group, age and the expression of PD-1 on T cells all showed no difference between severe sepsis with T2DM and severe sepsis without T2DM. PD-1 levels showed no significant difference between the SS group and the SS+T2DM group, suggesting that diabetes did not cause further immunosuppression in patients with severe sepsis, and whether diabetic immunosuppression
represents a risk factor for infection and how it affects progression of severe sepsis remain to be clarified.

This study also has some limitations. First, in order to demonstrate the effect of T2DM on immunity of patients with severe sepsis, this study selected infection-free T2DM patients that had a similar history of diabetes and similar medication as those patients with both T2DM and severe sepsis, however, the effect of some confounding factors, such as metabolic control, diabetes-related complications, obesity, and insulin or other medications, on the prognosis of severe sepsis with diabetes can not be ruled out [35]. Second, we did not calculate the absolute numbers of PD-1+ CD4+ and PD-1+ CD8+ T cells, the absolute numbers of PD-1+ CD4+ and PD-1+ CD8+ T cells may provide more precise information. Third, all patients with severe sepsis included in this study were selected from the emergency department, and the blood sample was taken only upon admission and without continuous monitoring; in addition, this study was performed in a single center, so the conclusion should be verified by future large-scale multi-center studies. At last, this is only an observational study, and the underlying molecular mechanism remains to be clarified.

Conclusions
The PD-1 levels were increased in peripheral blood CD4+ T cells and CD8+ T cells of both T2DM patients and those with severe sepsis, suggesting that both diseases involve immune suppression. However, combining T2DM did not cause a further increase in PD-1 levels among patients with severe sepsis, suggesting that diabetes did not cause further immune suppression, so whether diabetic immunosuppression represents a risk factor for infection and how it affect progression of severe sepsis remains to be investigated.

Supporting Information
S1 Checklist. SROBE checklist.
(DOC)

S1 Data. Raw data.
(XLS)

Acknowledgments
We wish to express our gratitude for the generosity of the patients who participated in this study. We sincerely thank the colleagues of our emergency department and endocrinology department for their excellent clinical assistance.

Author Contributions
Conceived and designed the experiments: YJ YZ CL. Performed the experiments: YJ YZ. Analyzed the data: YJ YZ RS. Contributed reagents/materials/analysis tools: CL. Wrote the paper: YJ YZ.

References
1. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306: 2594–2605. doi:10.1001/jama.2011.1829 PMID: 22187279
2. Koh GC, Peacock SJ, van der Poll T, Wiersinga WJ. The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis. 2012; 31: 379–388. doi:10.1007/s10096-011-1337-4 PMID: 21805196
3. Shu CJ, Benoist C, Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Semin Immunol. 2012; 24: 436–442. doi: 10.1016/j.smim.2012.12.001 PMID: 23333525

4. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11: 98–107. doi: 10.1038/nri2925 PMID: 21233852

5. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin superfamily, upon programmed cell death. Embo J. 1992; 11: 3887–3895. PMID: 1396582

6. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 190: 1027–1034. PMID: 11015443

7. Giancchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013; 12: 1091–1100. doi: 10.1016/j.autrev.2013.05.003 PMID: 23792703

8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19: 813–824. PMID: 17606980

9. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poilevin F, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit care. 2011; 15: R99. doi: 10.1186/cc10112 PMID: 21418617

10. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit care. 2011; 15: R70. doi: 10.1186/cc10059 PMID: 21349174

11. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8: 239–245. PMID: 17304234

12. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003; 198: 63–69. PMID: 12847137

13. Yadav D, Hill N, Yagita H, Azuma M, Sarvetnick N. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. Cell Immunol. 2009; 258: 161–171. doi: 10.1016/j.cellimm.2009.04.006 PMID: 19497561

14. Fujisawa R, Haseda F, Tsutsumi C, Hiromine Y, Noso S, Kawabata Y, et al. Low PD-1 expression in peripheral CD4+ T-cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol. 2015; 180: 452–457.

15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care. 2013; 36(Suppl.1): 67–74.

16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2013; 39: 165–228. doi: 10.1007/s00134-012-2769-8 PMID: 23361625

17. Donath MY. Targeting inflammation in the treatment of type 2 diabetes. Diabetes Obes Metab. 2013; 15 (Suppl. 3): 193–196. doi: 10.1111/dom.12172 PMID: 24003937

18. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007; 56: 2386–2397. PMID: 17579207

19. Jin C, Lu L, Zhang RY, Zhang Q, Ding FH, Chen QJ, et al. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta. 2008; 408: 45–49. doi: 10.1016/j.cca.2009.07.003 PMID: 19615354

20. Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes. 2007; 115: 38–41. PMID: 17286233

21. Fronczyk A, Moleda P, Safranow K, Piechota W, Majkowska L. Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation. 2014; 37: 349–357. doi: 10.1007/s10753-013-9746-4 PMID: 24197824

22. Shi B, Du X, Wang Q, Chen Y, Zhang X. Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. Metabolism. 2013; 62: 778–785. doi: 10.1016/j.metabol.2012.12.005 PMID: 23398844

23. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg. 2009; 108: 1841–1847. doi: 10.1213/ane.0b013e318195e11d PMID: 19448210
24. Huang X, Venet F, Wang YL, Lepape A, Yuan YP, Chen YP, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 2009; 106: 6303–6308. doi:10.1073/pnas.0809422106 PMID: 19332785

25. Brahmandam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010; 88: 233–240. doi:10.1189/jlb.0110037 PMID: 20483923

26. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit care. 2014; 18: R3. doi:10.1186/cc13176 PMID: 24387680

27. Rajasalu T, Brosi H, Schuster C, Spyrantis A, Boehm BO, Chen LP, et al. Deficiency in B7-H1 (PD-L1)/PD-1 Coinhibition Triggers Pancreatic beta-Cell Destruction by Insulin-Specific, Murine CD8 T-Cells. Diabetes. 2010; 59: 1966–1973. doi:10.2337/db09-1135 PMID: 20484136

28. Baban B, Liu JY, Mozaffari MS. Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1. Exp Mol Pathol. 2013; 94: 343–351. doi:10.1016/j.yexmp.2012.11.004 PMID: 23219834

29. Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005; 41: 281–288. PMID: 16007521

30. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003; 26:510–513. PMID: 12547890

31. Schuetz P, Jones AE, Howell MD, Trzcinski S, Ngo L, Younger JG, et al. Diabetes is not associated with increased mortality in emergency department patients with sepsis. Ann Emerg Med. 2011; 58: 438–444. doi: 10.1016/j.annemergmed.2011.03.052 PMID: 21683473

32. Chang CW, Kok VC, Tseng TC, Horng JT, Liu CE. Diabetic patients with severe sepsis admitted to intensive care unit do not fare worse than non-diabetic patients: a nationwide population-based cohort study. Plos one. 2012; 7: e50729. doi:10.1371/journal.pone.0050729 PMID: 23236389

33. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006; 34: 15–21. PMID: 16374151

34. Ginde AA, Moss M, Shapiro NI, Schwartz RS. Impact of older age and nursing home residence on clinical outcomes of US emergency department visits for severe sepsis. J Crit Care. 2013; 28: 606–611. doi:10.1016/j.jcrc.2013.03.018 PMID: 23683561

35. Schuetz P, Castro P, Shapiro NI. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes care. 2011; 34: 771–778. doi:10.2337/dc10-1185 PMID: 21357364